The presence and anti-HIV-1 function of tenascin C in breast milk and genital fluids

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Mansour, Robin G ^a   Stamper, Lisa ^a   Jaeger, Frederick ^a   McGuire, Erin ^a   Fouda, Genevieve ^a   Amos, Joshua ^a   Barbas, Kimberly ^b   Ohashi, Tomoo ^a   Alam, S Munir ^a   Erickson, Harold ^a   Permar, Sallie R ^a,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MILK PROTEIN; MONOCLONAL ANTIBODY; PROTEINASE; TENASCIN; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; HIV ENVELOPE PROTEIN GP120 (305-321); HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; PEPTIDE FRAGMENT; PROTEIN BINDING; RECOMBINANT PROTEIN;

ARTICLE; BREAST MILK; CERVICOVAGINAL LAVAGE FLUID; COLOSTRUM; CONTROLLED STUDY; ENZYME DEGRADATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MUCUS; NONHUMAN; PH; PROTEIN FUNCTION; SPERM; VAGINA; VAGINAL SECRETION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TRANSMISSION; DRUG EFFECTS; EXTRACELLULAR FLUID; GENITAL SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INNATE IMMUNITY; MALE; METABOLISM; MUCOSA; SECRETION (PROCESS); SERODIAGNOSIS; UTERINE CERVIX; VIROLOGY;

ANTIBODIES, NEUTRALIZING; CERVIX UTERI; EXTRACELLULAR FLUID; FEMALE; GENITALIA; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNITY, INNATE; IMMUNOGLOBULIN G; MALE; MILK PROTEINS; MILK, HUMAN; MUCOUS MEMBRANE; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECOMBINANT PROTEINS; SEMEN; TENASCIN;

EID: 84969509993     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155261     Document Type: Article

References (29)

1. "Beginning of the End of the AIDS Epidemic" (2014) UNAIDS The Gap Report. Available: http://www. unaids.org/sites/default/files/media-asset/UNAIDS-Gap-report-en.pdf.
2. Fouda GG, Yates NL, Pollara J, Shen X, Overman GR, Mahlokozera T, et al. Center for HIVAVI. 2011.HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. J. Virol. 85:9555-9567. doi: 10.1128/JVI.05174-11 PMID: 21734046
3. Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, et al. 2006. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol 13(10):1111-1118. PMID: 16928883
4. Newburg DS, Viscidi RP, Ruff A, Yolken RH. 1992. A human milk factor inhibits binding of human immunodeficiency virus to the CD4 receptor. Pediatr Res 31(1): 22-28. PMID: 1594326
5. Wahl A, Swanson MD, Nochi T, Olesen R, Denton PW, Chateau M, et al. 2012. Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog 8(6): e1002732. doi: 10.1371/journal.ppat.1002732 PMID: 22737068
6. Harmsen MC, Swart PJ, de Bethune MP, Pauwels R, De Clercq E, The TH, et al. 1995. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 172:380-8. PMID: 7622881
7. Moriuchi M, Moriuchi H. 2001. A milk protein lactoferrin enhances human T cell leukemia virus type I and suppresses HIV-1 infection. J Immunol 166:4231-6. PMID: 11238676
8. Malamud D, Nagashunmugam T, Davis C, Kennedy S, Abrams WR, Kream R, et al. 1997. Inhibition of HIV infectivity by human saliva. Oral Dis 3 Suppl 1:S58-63. PMID: 9456659
9. Farquhar C, Vancott TC, Mbori-Ngacha DA, Horani L, Bosire RK, Kreiss JK, et al. 2002. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis. 186(8):1173-6. PMID: 12355371
10. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. 1995. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 96(1):456-64. PMID: 7615818
11. Fouda GG, Jaeger FH, Amos JD, Ho C, Kunz EL, Anasti K, et al. 2013. Tenascin-C is an innate broadspectrum, HIV-1-neutralizing protein in breast milk. Proc. Natl. Acad. Sci. U. S. A., 110, pp. 18220-18225 doi: 10.1073/pnas.1307336110 PMID: 24145401
12. Midwood KS, Orend G. 2009. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 3:287-310. doi: 10.1007/s12079-009-0075-1 PMID: 19838819
13. Orend G, Chiquet-Ehrismann R. 2006. Tenascin-C induced signaling in cancer. Cancer Lett 244:143-63. PMID: 16632194
14. Erickson HP, Iglesias JL. 1984. A six-armed oligomer isolated from cell surface fibronectin preparations. Nature 311:267-269. PMID: 6482952
15. Sabatté J, Lenicov FR, Cabrini M, Rodriguez CR, Ostrowski M, Ceballos A, et al. 2011. The role of semen in sexual transmission of HIV: beyond a carrier for virus particles. Microbes Infect. 13:977-982.doi: 10.1016/j.micinf.2011.06.005 PMID: 21767659
16. Freel SA, Picking RA, Ferrari G, Ding H, Ochsenbauer C, Kappes JC, et al. 2012. Initial HIV-1 antigenspecific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J Virol. 2012; 86:6835-6846. doi: 10.1128/JVI.00437-12 PMID: 22514337
17. Bourdon MA, Wilkstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. 1983. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 43(6):2796-805. PMID: 6342760
18. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79(16):10108-10125. PMID: 16051804
19. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 46(6):1896-1905. PMID: 12019106
20. Haugen TB, Grotmol T. 1998. pH of human semen. Int J Androl. 21(2):105-8. PMID: 9675619
21. O'Hanlon DE, Moench TR, Cone RA. 2013. Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS One. 8(11):e80074. doi: 10.1371/journal.pone.0080074 PMID: 24223212
22. Owen DH, Katz DF. 1999. A vaginal fluid simulant. Contraception. 59(2):91-5. PMID: 10361623
23. Seaman M S, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 13 84:1439-145
24. Semba RD, Kumwenda N, Hoover DR, Taha TE, Quinn TC, Mtimavalye L, et al. 1999. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 180(1):93-8. PMID: 10353866
25. Filteau SM, Rice AL, Ball JJ, Chakraborty J, Stoltzfus R, de Francisco A, et al. 1999. Breast milk immune factors in Bangladeshi women supplemented postpartum with retinol or beta-carotene. Am J Clin Nutr. 69(5):953-8 PMID: 10232636
26. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. 2009. Broad and potent neutralizing antibodies from and African donor reveal a new HIV-1 vaccine target. Science 326:285-289.doi: 10.1126/science.1178746 PMID: 19729618
27. Coutsoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, Harris DR, et al. 2004. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis. 189 (12):2154-66. PMID: 15181561
28. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. 2009. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 9(2):118-29. doi: 10.1016/S1473-3099(09)70021-0 PMID: 19179227
29. Powers KA, Poole C, Pettifor AE, Cohen MS. 2008. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis. 8(9):553-63. doi: 10.1016/S1473-3099(08) 70156-7 PMID: 18684670